Nanobac Pharmaceuticals, Incorporated
NNBP
$0.00
$0.000.00%
OTC PK
| 12/31/2007 | 09/30/2007 | 06/30/2007 | 03/31/2007 | 12/31/2006 | |
|---|---|---|---|---|---|
| Revenue | 17.60K | 15.50K | 33.60K | 68.80K | 225.10K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 17.60K | 15.50K | 33.60K | 68.80K | 225.10K |
| Cost of Revenue | 14.60K | 11.60K | 18.20K | 38.90K | 79.80K |
| Gross Profit | 3.10K | 4.00K | 15.50K | 29.90K | 145.20K |
| SG&A Expenses | 2.83M | 2.92M | 3.03M | 3.02M | 1.28M |
| Depreciation & Amortization | 460.30K | 463.90K | 467.20K | 469.70K | 541.30K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.45M | 5.17M | 5.38M | 5.55M | 3.89M |
| Operating Income | -4.43M | -5.15M | -5.35M | -5.48M | -3.67M |
| Income Before Tax | -6.58M | -6.71M | -6.66M | -6.78M | -4.41M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -6.58 | -6.71 | -6.66 | -6.78 | -4.41 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6.58M | -6.71M | -6.66M | -6.78M | -4.41M |
| EBIT | -4.43M | -5.15M | -5.35M | -5.48M | -3.67M |
| EBITDA | -3.97M | -4.69M | -4.88M | -5.01M | -3.13M |
| EPS Basic | -0.03 | -0.03 | -0.03 | -0.03 | -0.02 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.01 | -0.02 | -0.01 |
| EPS Diluted | -0.03 | -0.03 | -0.03 | -0.03 | -0.02 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.01 | -0.02 | -0.01 |
| Average Basic Shares Outstanding | 978.49M | 933.65M | 888.89M | 839.50M | 797.56M |
| Average Diluted Shares Outstanding | 978.49M | 933.65M | 888.89M | 839.50M | 797.56M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |